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In Alzheimer’s disease (AD) and other tauopathy, Tau proteins form 
intracellular aggregates and Tau filaments. These tau oligomers are known as 
one of major cause of neurotoxicity in tauopathy. However, the mechanisms 
that regulate Tau aggregation are not fully understood. In this study, I 
approached animal model to better understand the mechanism by generating 
tau transgenic mouse model showing tau oligomers and by isolating tau 
aggregation regulator. 
 In the AD brain, activated caspases cleave tau at the 421th Asp, generating 






rapidly into filaments in vitro, a role of TauC3 in vivo remains unclear. Here, 
I generated a transgenic mouse expressing human TauC3 using a neuron-
specific promoter. In this mouse, I found that human TauC3 was expressed in 
the hippocampus and cortex. Interestingly, TauC3 mice showed drastic 
learning and spatial memory deficits and reduced synaptic density at a young 
age (1.3–3 months). Notably, tau oligomers as well as tau aggregates were 
found in TauC3 mice showing memory deficits. Further, i.p. or i.c.v. injection 
with methylene blue or Congo red, inhibitors of tau aggregation in vitro, and 
i.p. injection with rapamycin significantly reduced the amounts of tau 
oligomers in the hippocampus, rescued spine density, and attenuated memory 
impairment in TauC3 mice. Together, these results suggest that TauC3 
facilitates early memory impairment in transgenic mice accompanied with tau 
oligomer formation, providing insight into the role of TauC3 in the AD 
pathogenesis associated with tau oligomers.  
Also, in this study, we show that POLDIP2 is a novel regulator of Tau 
aggregation. From a cell-based screening using cDNA expression library, we 
isolated POLDIP2 which increased Tau aggregation. Expression of POLDIP2 
was increased in neuronal cells by the multiple stresses, including A, TNF-
 and H2O2. Accordingly, ectopic expression of POLDIP2 enhanced the 






down-regulation of POLDIP2 alleviated ROS-induced Tau aggregation. 
Interestingly, we found that POLDIP2 overexpression induced impairments 
of autophagy activity and partially proteasome activity and this activities were 
retained in DUF525 domain of POLDIP2. In a drosophila model of human 
tauopathy, knockdown of the drosophila POLDIP2 homolog, CG12162, 
attenuated rough eye phenotype induced by Tau overexpression. Further, the 
lifespan of neural-TauR406W transgenic files were recovered by CG12162 
knockdown. Together, these observations indicate that POLDIP2 plays a 
crucial role in Tau aggregation via the impairment of autophagy activity, 
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In neurodegenerative diseases like Alzheimer’s disease (AD), tau is 
hyperphosphorylated and forms neurofibrillary tangles in affected neurons. 
In the AD brain, activated caspases cleave tau at the 421th Asp, generating a 
caspase-cleaved form of tau, TauC3. However, its role in AD pathogenesis 
remains unclear. To evaluate in vivo activity of TauC3, I generated a 
transgenic mouse expressing human TauC3 using a neuron-specific promoter. 
In this mouse, I found that human TauC3 is expressed in the hippocampus, 
cortex, and cerebellum with comparable level to mouse tau. TauC3 mice 
showed drastic learning and spatial memory deficits and reduced synaptic 
density at a young age (2–3 months). Compared to control mice, tau protein 
in TauC3 mice was highly phosphorylated at many epitopes, including PHF-
1 and AT100. Notably, both detergent-soluble tau oligomers and detergent-
insoluble tau aggregates were found in TauC3 mice showing memory deficits 
and its level increased during aging. Intraperitoneal injection of TauC3 mice 
with methylene blue, an inhibitor of tau aggregation in vitro, significantly 
reduced the amounts of tau oligomers and aggregates in the hippocampus and 
attenuated memory impairment. Together, these results suggest that TauC3 






memory impairment in transgenic mice, providing insight into the role of 









Tau is a neuronal microtubule-associated protein that binds to and stabilizes 
microtubules in axons (Schweers et al., 1994). In AD and other tauopathies, 
Tau is hyperphosphorylated and forms insoluble aggregates called 
neurofibrillary tangles (NFTs) in neurons (Lee et al., 2001). While NFTs are 
considered as a hallmark of AD (Braak and Braak, 1991), it is unlikely that 
NFTs are the major toxic Tau species (Santacruz et al., 2005). Recently, Tau 
oligomers and aggregates were detected in the brain of AD model mice and 
proposed to play an important role in AD pathogenesis (Berger et al., 2007). 
It appears that intermediate forms of Tau, which are highly phosphorylated, 
may form before the NFT development and mediate neuronal dysfunction 
(Lasagna-Reeves et al., 2011).  
Many Tau mouse models have been established for studying tauopathy. 
Because normal Tau protein is too soluble to form Tau aggregates, however, 
transgenic (TG) mice expressing wild-type human Tau or Tau kinase do not 
show either NFTs or memory loss in most cases (Duff et al., 2000; Gotz et al., 
1995; Lucas et al., 2001). Tau TG model expressing a missense mutation 






chromosome 17 (FTDP-17) patient reveals neuronal loss with 
hyperphosphorylated Tau and an NFT-like Tau aggregate, but no associated 
memory deficits (Lewis et al., 2000). rTG4510, a TRE-inducible mouse 
model overexpressing P301L Tau mutant, shows memory loss with 
hyperphosphorylated Tau at early age and NFT formation at middle age 
(Santacruz et al., 2005). However, overexpression of P301L Tau mutant is too 
high in this case. Also, in AD and other tauopathy without FTDP-17, P301L 
mutation is not found in Tau gene despite there being an aggregation of Tau 
in neurons (Wolfe, 2009). Currently, existing mouse models are not sufficient 
to describe the spectrum of tauopathy, especially Tau oligomers and 
aggregates-associated memory impairment. 
Because of Aβ and stress, caspases are activated in the AD brain and cleave 
multiple proteins, including Tau (Rohn et al., 2002). TauC3 has been shown 
to form Tau oligomers and aggregates faster than wild-type Tau in vitro 
(Gamblin et al., 2003), and localized within Tau aggregates in P301S and 
rTG4510 mice (Delobel et al., 2008; Zhang et al., 2009). In the brain of 
rTG4510 mice, caspase activation leads to the formation of tangles in cells 
just a day after and TauC3 is found in tangles (de Calignon et al., 2010). In 
addition, TauC3 is typically found in the brain of patients at the mild cognitive 






with other tauopathies, including Pick’s disease (Mondragon-Rodriguez et al., 
2008), corticobasal degeneration (Newman et al., 2005), progressive 
supranuclear palsy (Guillozet-Bongaarts et al., 2005), and traumatic brain 
injury (Gabbita et al., 2005). These data indicate that TauC3 is associated with 
Tau aggregates. However, the role of TauC3 in AD pathogenesis, whether 
TauC3 is byproduct or cause of the pathology, remains unknown.  
In this study, I show that transgenic expression of TauC3 in the mouse 
brain induces memory impairment at a young age, which is accompanied by 
the appearance of Tau oligomers and aggregates. Aggregation blockers, such 
as methylene blue and Congo red, inhibit Tau aggregation and prevent 
memory impairment in the TauC3 mice. Thus, TauC3 oligomers and 







Materials and methods 
 
 
Generation of TauC3 mice 
The human tau expression construct was injected into embryos and positive 
F0 mice were identified by PCR analysis using a synthetic oligonucleotide 
(forward; 5′-GGA TGG CTG AGC CCC GCC CGG AGT TCG-3′) 
corresponding to the BAI1-AP4 promoter and an oligonucleotide (reverse; 5′-
GGG CTG CTC GCG GTG TGG CGA TCT TC-3′) of tau cDNA (Macrogen 
Inc., Korea). TauC3 mouse was identified and mated to FVB WT mice to 
generate a pure FVB genetic background for the F2 generation, and F3 
offspring was then backcrossed to BALB/C mice under a 12: 12 h of light: 
dark cycle with access to food and water ad libitum. 
 
Western blot analysis 
The cortex, hippocampus, cerebellum, striatum, and other brain regions were 
prepared from TauC3 mice and age-matched littermates (6 to 10 mice per age). 
Subsectioned brain tissues were grinding with a mortar and pestle in liquid 
nitrogen and powdered tissues stored at - 80°C until use. The powdered 






First, TBS extraction buffer [20 mM Tris-Cl (pH 7.4), 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 1 mM Na3VO4, and 20 mM NaF with 
0.5 % NP-40] to detect tau phosphorylation. Second, oligomer extraction 
buffer [20 mM Tris-Cl (pH 7.4), 0.8 M NaCl, 10 % sucrose, 1 mM ethylene 
glycol tetraacetic acid (EGTA), 1 mM PMSF, 1 mM Na3VO4, 20 mM NaF, 
and 0.5 % NP-40] containing 2 mM NEM. Third, RAB buffer [0.1 M 2-(N-
morpholino) ethanesulfonic acid (MES) pH 7.0, 1 mM EGTA, 0.5 mM 
MgSO4, 0.75 M NaCl, 1 mM PMSF, 1 mM Na3VO4, and 20 mM NaF] and 
RIPA buffer, (50 mM Tris-Cl pH 8.0, 150 mM NaCl, 0.5 % NP-40, 5 mM 
EDTA, 0.5 % sodium deoxycholate, and 0.1 % SDS) were prepared to 
solubilize RIPA-insoluble Tau. Samples were then solubilized in SDS sample 
buffer with or without β-mercaptoethanol to examine different Tau species 
with Western blotting. 
 
Antibodies 
TG5 (total Tau: detects epitope a.a.220-240, 1:1,000), PHF-1 [p-Tau: 
Ser396/404, later-stage NFTs (Uboga NV and Price JL., 2000), 1:3,000], 
CP13 (p-Tau: Ser202, 1:1,000), and MC1 [a conformational abnormality of 
Tau (Jicha et al., 1997), 1:500 antibody] were kindly gifted from Dr. P. Davies 






Ser262/Ser356, 1:3,000) was kindly gifted from Dr. P. Seubert (Elan 
Pharmaceuticals, MA, USA). AT8 (p-Tau: Ser202/205, 1:3,000), AT100 [p-
Tau: Ser212/214, Alzheimer-associated abnormal Tau (Weaver et al., 2000), 
1:5,000], pT231 (p-Tau: Ser231, 1:3,000), and HT7 (human Tau-specific: 159 
and 163, 1:5,000) antibodies were purchased from Thermo scientific (IL, 
USA). TauC3 (1:2,500) antibody was from Invitrogen (CA, USA) and Tau3 
antibody (1:100) was generated against a peptide containing Asp421. ATG5 
(1:2,000), LC3 (1:3,000), and p62 (1:1,000) antibodies were from Novus 
biologicals (CO, USA). P-S6 (1:1,000) PSD95 (1:1,500), NR1 (1:1,000), 
NR2A (1:1,000) and NR2B (1:1,000) antibodies were from Cell signaling 
(MA, USA). Tubulin (1:10,000) and β-actin (1:10,000) antibodies were from 
Santa Cruz biotechnologies (DL. USA). Secondary mouse (1:10,000) and 
rabbit (1:10,000) antibodies conjugated to peroxidase were purchased from 
Jackson Immunoresearch (PA, USA). 
 
Cell culture, DNA construction, and DNA transfection 
SH-SY5Y (human neuroblastoma) cells and primary hippocampal neurons 
were prepared as described previously (Park et al., 2012). Briefly, SH-SY5Y 
cells were cultured in DMEM (Hyclone) supplemented with 10 % (v/v) fetal 






postnatal day 1 and incubated for 13 days in neurobasal media containing B27 
(Invitrogen). SH-SY5Y cells were transfected using the Polyfect reagent 
(Quiagen), whereas primary neurons were transfected using the 
Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s 
instructions. Tau-GFP and TauC3-GFP constructs were described previously 
(Chung et al., 2001). 
 
Dendritic spine density analysis 
Dendritic spine density analysis was described previously (Kam et al., 2013). 
In brief, cultured hippocampal primary neurons were transfected at 13 days 
in vitro (DIV) with EGFP-fusion construct for 24 h. Images of GFP-
expressing cells were acquired by confocal microscopy (Carl Zeiss) and the 
numbers of spines on the axon (100 μm in length) of randomly chosen 
neurons were counted on the images (n = 6 ~ 10). 
 
In vitro Tau fibrillation and thioflavin T fluorescence assay 
Tau construct was previously described (Chung et al., 2001). Human full-
length tau (0N4R) was subcloned into pET28a containing histidine (His6x) 
(Invitrogen) to generate His-fusion protein (pHis6x-Tau) and Tau protein was 






Total 10 μM Tau protein was incubated with 50 mM NH4Ac buffer containing 
20 μM heparin and 2 mM dithiothreitol at 37°C. The reaction products were 
then incubated with 25 μM thioflavin T (Sigma) (final concentration was 5 
μM) and fluorescence was measured with a LS-50 fluorimeter (Perkin-Elmer) 
using an excitation filter of 450 nm and an emission filter of 484 nm. 
 
Filter trap assay  
The filter trap assay of Tau protein was performed as previously described 
(Park et al., 2012). Tissue extracts were prepared in TBS extraction buffer by 
sonication. After centrifugation at 15,000x g for 30 min at 4°C, the 
supernatants were incubated with 0.1 % SDS for 30 min. After incubation, 
supernatants were filtered through nitrocellulose membrane (0.2 μm) (Pall 
industries) by using a 96-well vacuum dot blot apparatus (Bio-Rad 
laboratories). The membrane was washed twice with TBST, blocked with 
TBST containing 5 % non-fat milk for 1 h, and analyzed by Western blotting. 
 
Histology and immunohistochemistry 
Mice were transcardially perfused with ice-cold PBS before dissection of the 
tissue post fixation. Histological and immunohistochemical analysis were 






Immunohistochemistry was done using standard immunoperoxidase 
procedures with Elite ABC kits (Vector Laboratories) and developed with 3,3-
diaminobenzidine. The following monoclonal antibodies were used to stain 
the free-floating brain sections: HT7 (1:100), TauC3 (1:50), PHF-1 (1:100), 
AT100 (1:1000), T22 (1:100), MC-1 (1:10), synaptophysin (1:100, Santa 
Cruz Biotechnology), and GFAP (1:1000, Santa Cruz Biotechnology). 
 
Behavior tests 
Behavior test was performed as previously described (Kam et al., 2013). 
TauC3 mice and age-matched wild-type controls (were tested for 3 different 
types of memory and 1 motor function: Y-maze test has been longitudinally 
performed from 1.3 to 6 months of age for 3 week interval (between 1.3 and 
2 month) and for 1 month interval (from 2 to 6 months) for spatial memory. 
Noble object recognition and passive-avoidance tests were done from 1.3 to 
6 months of age and wire-hang test was performed to evaluate motor function 
and deficit. Number of animals are different and both male and females are 
used. (n = 11–19 mice per group. Figure 2; WT, 10 males and 8 females; 
TauC3, 10 males and 9 females. Figure 6; WT PBS, 6 males and 5 females; 
WT methylene blue, 5 males and 6 females; TauC3 PBS, 10 males and 8 






6 males and 5 females.  Figure 8; WT PBS, 6 males and 6 females; WT 
rapamycin, 7 males and 6 females; TauC3 PBS, 10 males and 9 females; 
TauC3 rapamycin, 8 males and 9 females.) 
Y-maze: This test is well known to evaluate spatial memory of mice. 
A triangular Y-maze was made from black plastic with arm size of 32.5 cm x 
15 cm (length x height). For the test, mice were placed in the end of one arm 
and allowed to move freely through the maze for 7 min. An entry was defined 
as placing all four paws into the arm. The percentage of spontaneous 
alterations was calculated as the ratio of the number of successful alterations 
to the number of total alterations. After each trial, the maze was cleaned with 
70 % ethanol.  
Y-maze spontaneous alternation test: This is a behavioral test for 
measuring hyperactivity and general locomotor activity. Method is similar 
with Y-maze test; mice were placed in the end of one arm and allowed to 
move freely through the maze for 7 min, but instead ratio of the number of 
successful alterations, total number of arm entry were counted and identified 
as hyperactivity and locomotor activity. 
Novel object recognition test: This test is to evaluate cognition, 
particularly recognition memory of mice. Mice were first habituated in a 






24 h intervals. After 2 days (training trial), the mice were presented with two 
objects and allowed to explore freely for 7 min. In the testing trial, performed 
24 h later, one of the familiar objects was changed for a novel object and mice 
were scored for recognition during 7 min. The object recognition was defined 
as spending time with orienting toward the object in a distance of 1 cm or less, 
sniffing the object or touching with the nose. Between each trial, the arena 
and objects were wiped down with 70 % ethanol.  
Passive avoidance: The passive avoidance apparatus consists of a light 
(white) and dark (black) compartments (20 x 20 x 20 cm each) separated by 
a guillotine door. The floor of the dark compartment was made of stainless-
steel grids. During habituation, mice were allowed to freely explore the box 
for 5 min with the door open and then returned to their home cage. For 
conditioning, after 24 h, mice were placed into the light compartment and the 
sliding door was closed when both hind limbs of mice were entered into the 
dark box and an electric foot shock (0.2 mA, 1 sec) was then delivered by the 
floor grids. Ten seconds later, the mice were returned to their home cage. 
Tests were carried out 24 h after the conditioning and the latency time for 
mice to enter the dark compartment was measured with a 7 min cut-off. 
Wire-hang test: The test began with the animal hanging from an elevated 






inverted and suspended above the home cage 60 cm high. When mice fell 
down, latency to fall was recorded. 
 
Intracerebroventricular injection of Aβ oligomers 
Generation of Aβ1-42 (Aβ) oligomers and intracerebroventricular 













Generation of a neuron-specific TauC3 transgenic mouse.  
To examine the role of TauC3 in memory impairment, I generated TauC3 
mice expressing a short isoform of 4 repeat (0N4R) human Tau lacking the 
C-terminus 20 amino acids. Caspase cleavage product of 0N4R Tau (0N4R 
tau1-363) corresponding to 2N4R Tau (2N4R tau1-421) was expressed under the 
control of a brain-specific angiogenesis inhibitor 1-associated protein 4 
(BAI1-AP4) promoter (Kim et al., 2004). The BAI1-AP4 promoter in the 
BAI1-AP4/β-galactosidase transgenic mice drives neuron-specific 
expression of β-galactosidase in the sub-regions of the brain, mainly in the 
cortex and hippocampus. Accordingly, the results from Western blot analysis 
using human Tau-specific HT7 antibody revealed that TauC3 with a 
molecular weight of 50 kDa was detected in a number of brain areas, 
including the cortex, hippocampus, striatum, and cerebellum of TauC3 mice 
(Fig. 1-2A). Using TauC3 antibody, a caspase 3-cleaved Tau-specific 
antibody (Gamblin et al., 2003), I also found the same size of Tau protein only 
in TauC3 mice but not in wild-type mice (Fig. 1-2A). On the other hand, 







When I examined both mouse and human Tau proteins by Western blot 
analysis using TG5 antibody, the amount of total Tau protein was about 16% 
(cerebellum) to 54% (hippocampus) higher in TauC3 mice than in wild-type 
littermates (Fig. 1-2B). Examination of tissue- and cell type-specific 
expression of TauC3 using immunohistochemical analysis revealed that HT7-
positive human TauC3 was largely expressed in the cortex and hippocampus 
of TauC3 mice (Fig. 1-1B). In addition, HT7 and TauC3 antibodies detected 
human TauC3 in the layer I to II of cerebral cortex, and in the CA3 pyramidal 
cell layer and mossy fiber layer of the hippocampus in TauC3 mice (Fig. 1-
3), important regions for spatial memory and long-term memory 
consolidation. 
 
Impaired memory function and reduced synaptic density in TauC3 mice 
at an early age. 
 I then measured memory function of TauC3 mice. The results from Y-maze 
test revealed that spatial working memory was drastically impaired at 2 
months and completely lost at 4 months in TauC3 mice (0.73 to 0.55) (Fig. 1-






exploring the novel object than the object previously explored 1 day before 
(Fig. 1-4B). In contrast, TauC3 mice showed impaired preference to the new 
object at when they were 2 months old, and this impairment continued to 
worsen until 5 months of age (67 % to 56 %). In both tests, memory function 
started to be impaired as early as at 1.3 months in TauC3 mice (Fig. 1-4A and 
B). I also examined TauC3 mice on passive avoidance memory test. During 
training, learning and memory represented by escape latency was slowed at 
around 2 months in TauC3 mice. Specifically, TauC3 mice showed a deficit 
in recalling an electric shock given a day before, in which escape latency 
decreased from 363 sec to 78 sec during 1.3 to 5 months of age (Fig. 1-4C). 
Together, these results suggest that TauC3 mice show learning and memory 
impairments as early as 2 months of age. While TauC3 was detected in the 
cerebellum of the transgenic mice, wire-hang test revealed little difference 
between TauC3 and age-matched wild-type mice in motor weakness or 
muscle atrophy (Fig. 1-5A) and Y-maze spontaneous alternation test showed 
no difference in hyperactivity (Fig. 1-5B). 
Because synaptic integrity is closely associated with memory function in 
AD, I compared synaptic density in aging TauC3 and wild-type mice. An 
immunohistochemical analysis revealed that the synaptophysin, a synaptic 






decrease in the hippocampal CA3 mossy fiber layer in 1.3 month-old TauC3 
mice and were more reduced at 3 months compared to control littermates (Fig. 
1-6A and B). Investigation of the synaptic proteins with Western blotting 
revealed that the levels of postsynaptic density-95 (PSD95), N-methyl-D-
aspartic receptors 1 (NR1), and 2B (NR2B) significantly decreased in the 
hippocampus of 3 and 6 month-old TauC3 mice (Fig. 1-6C and D). Together 
with the memory impairments, age-dependent reduction of synaptic density 
in TauC3 mice may cause the observed memory impairment through synaptic 
dysfunction.  
On the other hand, examination of cell death showed a few of TUNEL-
positive signals (1.25 ~ 3.25/mm2) in the hippocampus and cortex of 6 month-
old TauC3 mice and its increase in 12 month of age (Fig. 1-7) but no 
significant reduction in total cell numbers of the affected tissues (Fig. 1-8). 
There was no significant difference in life span until 22 months between wild-
type and TauC3 mice (Fig. 1-9). 
 
Appearance of Tau oligomers in TauC3 mice showing memory deficit.  
To gain insight into the mechanism by which TauC3 produces memory 






various phospho-Tau-specific antibodies, I found that Tau phosphorylation at 
PHF-1 (Ser 396/404) epitope was already detected in the hippocampus of 1.3 
month-old TauC3 mice and increased further until 3 months (Fig. 1-10). 
Additionally, conformation change of Tau protein detected by an MC-1 
antibody was apparent in the brains of 1.3 and 2 month-old TauC3 mice (Fig. 
1-10). These data show that Tau hyperphosphorylation occurs in TauC3 mice 
showing memory impairment. 
Different Tau species, frequently seen as both detergent-soluble and -
insoluble Tau, have also been implicated in AD pathogenesis (Hanger et al., 
1991; Kopeikina et al., 2012). Thus, I investigated the presence of detergent-
soluble Tau oligomers in TauC3 mice. To identify the Tau oligomers, mouse 
hippocampal lysates were resolved in the lysis buffer containing N-
ethylmaleimide (NEM) which protects native disulfide bonds but prevents 
non-specific disulfide bond formation after cell lysis (Molinari and Helenius, 
1999). Unlike reducing condition, a Western blot analysis under a non-
reducing condition lacking β-mercaptoethanol and DTT revealed a high 
molecular weight (around 170 kDa) of human Tau (HT7) in TauC3 mice but 
not in wild-type littermates. (Fig. 1-11A). Interestingly, 170 kDa human Tau 
was first observed in the hippocampus of TauC3 mice at 1.3 month of age and 







On the contrary, Western blotting using a TG5 antibody under the same 
condition revealed that the half of the total Tau protein was detected at 50 kDa 
and the other half at 170 kDa. The majority of Tau signal was detected at 170 
kDa in TauC3 mice by PHF-1, MC-1, and Tau oligomer-specific T22 
(Lasagna-Reeves et al., 2012) antibodies and these signals further increased 
with aging (Fig. 1-11B and C). Analysis of other AD model mice, 3X TG 
mice which express APPswe, PS, and Tau P301L (Oddo et al., 2003), revealed 
the presence of both 170 kDa and 50 kDa human Tau in 9 month-old mice 
showing memory impairment but 170 kDa Tau was not in 2 month-old mice 
with normal memory function (Fig. 1-11D). From an immunohistochemical 
analysis, I also observed the hyperphosphorylated Tau oligomers in the 
hippocampus of TauC3 mice; HT7- and T22-positive Tau oligomers were 
localized in the pyramidal cell layer and PHF-1-positive Tau in the mossy 
fiber layer of the hippocampal CA3 region (Fig. 1-12). Together, the results 
indicate that TauC3 in TauC3 mice is present exclusively as oligomers which 
are highly phosphorylated. Additionally, from immunohistochemical analysis, 
I found that caspase inhibitor blocked the formation of T22-positive Tau 
oligomers and the loss of synaptic density in Aβ oligomer-treated primary 






caspase inhibitor blocked the generation of TauC3 and T22-positive Tau 
oligomers in the brain of the mice showing memory deficit (Fig. 1-14), 
demonstrating the pathophysiologic role of endogenous TauC3 in mice. 
 
Accumulation of detergent-insoluble Tau aggregates in TauC3 mice.  
To examine detergent-insoluble Tau aggregates, Tau protein was serially 
extracted from hippocampal lysates into an aqueous-soluble (RAB), detergent 
(NP-40)-soluble, and detergent-insoluble but 70 % formic acid (FA)-soluble 
Tau fractions. A Western blot analysis of the fractions with a TG5 antibody 
revealed that compared to wild-type mice, the total amount of detergent-
insoluble but FA-soluble Tau was detected in the brain of TauC3 mice at 1.3 
months and increased in TauC3 mice in an age-dependent manner (Fig. 1-15A 
and B). Interestingly, HT7-positive human TauC3 and MC-1-positive Tau 
with conformational change were detected in the detergent-insoluble fraction 
and their amounts increased during aging of TauC3 mice, although there was 
some variation between the mice.  
Similarly, a filter trap assay followed by a dot blot analysis revealed that 
sodium dodecyl sulfate (SDS)-resistant insoluble Tau aggregates were 






1-15C and D). These results indicate that NP-40- or SDS-insoluble aggregates 
of Tau as well as Tau oligomers accumulate in the hippocampus of TauC3 
mice showing memory impairment. Moreover, silver staining-positive Tau 
aggregates were detected at 3 months in the cortex and hippocampus of 
TauC3 mice and further increased at 6 months (Fig. 1-16A). Electron 
microscopic analysis following an immunoprecipitation assay also showed 
Tau aggregates with filamentous structure in 1.3 month-old TauC3 mice and 
more of them in 6 month-old TauC3 mice (Fig. 1-16B), as Tau oligomers and 
detergent-insoluble Tau aggregates increased with aging.  
 
Methylene blue improves memory function and synaptic density with 
reduced Tau oligomers in TauC3 mice.  
To investigate the pathologic significance of Tau oligomers and aggregates, 
I decided to test the effect of methylene blue and Congo red, which are 
supposed to be β-sheet aggregation blockers, on the pathology in TauC3 mice. 
Methylene blue is now in phase III clinical trials for drug development in AD 
(Gravitz, 2011), but the mechanisms by which it alleviates AD pathology are 
not yet clearly shown. As reported (Pickhardt et al., 2005), our results from 






began to form thioflavin T (ThT)-positive aggregates in the presence of 
heparin (Fig. 1-17A). Expectedly, the formation of Tau aggregates was 
hampered by the addition of methylene blue. In SH-SY5Y cells, methylene 
blue reduced the amount of filter-trapped Tau aggregates (Fig 1-17B). These 
results indicate that methylene blue blocks the formation of Tau aggregates in 
vitro and in cells. Please note that high dose of methylene blue could reduce 
the amount of total Tau as well in cells (Fig 1-17B). Congo red is also known 
to ameliorate the pathogenesis of Huntington’s disease and binds to β-sheet 
aggregates (Sanchez et al., 2003). In our assay, Congo red also inhibited the 
formation of Tau aggregates (Fig. 1-17B). 
Then I addressed the effects of these molecules on the memory in TauC3 
mice. After daily i.p.-injection of methylene blue for 30 days or biweekly 
intracerebroventricular (i.c.v.)-injection with Congo red (Fig. 1-18A), 
memory in TauC3 mice was examined. Spatial and recognition memories in 
TauC3 mice were not impaired by the treatment with methylene blue and less 
but still significantly by Congo red (Fig. 1-18B). In contrast, daily i.p.-
injection of Congo red did not affect memory impairment in TauC3 mice (Fig. 
1-19). It may be due to the poor ability of Congo red to penetrate the blood-
brain barrier (Wood et al., 2007). These results indicate that Tau aggregation 






impairment in TauC3 mice. 
When I analyzed the effect of methylene blue on the formation of Tau 
oligomers, Western blot analysis revealed that the amount of Tau oligomers 
(170 kDa) was remarkably reduced in TauC3 mice after exposure to 
methylene blue (Fig. 1-20). In the same tissue, the amount of total Tau (TG5) 
was a little reduced by methylene blue, whereas TauC3 (HT7) and PHF-1 Tau 
were largely affected (Fig. 1-21). An immunohistochemical analysis showed 
similar patterns; TauC3 and T22-positive Tau oligomers were apparently 
reduced in TauC3 mice (Fig. 1-22). Interestingly, unlike full-length Tau, 
overexpression of TauC3 alone or co-expression with full-length Tau 
apparently reduced spine density in the primary hippocampal neurons (Fig. 
1-23A and B). Consistent to the previous reports (Gamblin et al., 2003; 
Rissman et al., 004), TauC3 stimulated the formation of ThT-positive Tau 
filaments and aggregates in vitro and in cells. Moreover, methylene blue was 
potent to block the loss of spine density triggered by TauC3 in cultured 
neurons (Fig. 1-23A and B) and rescued the loss of synaptic proteins, such as 
PSD95 and NR1, in TauC3 mice (Fig. 1-23C). 
 






I further examined the effects of rapamycin, a mTOR inhibitor and 
autophagy inducer that has been tested in Huntington’s disease, Parkinson’s 
disease, and AD (Bove et al., 2011; Caccamo et al., 2010; Ravikumar et al., 
2004), on clearing the aggregated Tau. One month-old TauC3 mice were daily 
injected with rapamycin for 30 days and examined for memory impairment. 
On a Y-maze test at 30 days after drug treatment, rapamycin rescued memory 
impairment in TauC3 mice (56.5 % to 65.4 %) almost to the control level 
(68.4 %). Novel object recognition test also illustrated that recognition 
memory was improved (0.57 to 0.66). On both tests, rapamycin did not 
significantly affect memory in wild-type mice. (Fig. 1-24) 
Rapamycin greatly reduced the levels of phospho-Tau (PHF-1) and AT100-
positive soluble Tau in TauC3 mice, while the level of total Tau was not much 
changed, and reduced the amounts of NP-40-soluble PHF-1 Tau and NP-40-
insoluble (70% FA-soluble) Tau aggregates (Fig. 1-25). In the same 
experiments, I found that the level of LC3-II, an autophagy marker (Kabeya 
et al., 2000), increased in the brain of TauC3 mice, while p62, an ubiquitin-
binding autophagy marker (Pankiv et al., 2007), decreased by rapamycin (Fig. 
1-26). As expected, rapamycin seemed to enhance autophagy flux in the brain 
of TauC3 mice. Western blot analysis under non-reducing condition revealed 






mice but less than methylene blue (Fig. 1-27). It appears that rapamycin 
functions to improve memory in TauC3 mice with enhanced clearance of Tau 
oligomers and aggregates, probably due to its stimulatory effects on 
autophagy.  
Together with the memory rescue effects by methylene blue and rapamycin, 
both of which were shown to affect the amounts of Tau oligomers and 
aggregates, respectively, TauC3 mouse may be a useful AD model to 
elucidate Tau oligomer-associated pathogenesis of tauopathy and to evaluate 







Figure 1-1 TauC3 mice display neuronal-specific expression of human tau. 
(A) Neuronal expression of TauC3. The cortex, hippocampus, spinal cord, 
heart, lung, liver, kidney, and spleen were isolated from 1.3 month-old wild-
type (WT) and TauC3 mice and tissue extracts were analyzed by Western 
blotting using human Tau-specific HT7 antibody. n.s.; non-specific signal. (B) 
Immunohistochemical analysis showing the regional expression of TauC3 in 
the cortex (a) and hippocampus (b) of 1.3 month-old TauC3 transgenic mice. 














Figure 1-2 Expression of human caspase-cleaved Tau in the brain region 
of cortex, hippocampus, cerebellum and striatum of transgenic mice. 
(A) Transgenic expression of human TauC3 in the mouse brain. Tissue 
extracts from 1.3-month-old wild-type (WT) and TauC3 mice were analyzed 
by Western blotting using human Tau (HT7), TauC3-specific (TauC3), and 
total Tau (TG5) antibodies. (B) Densitometric analysis of total human 













Figure 1-3. Human TauC3 is expressed in cortex and hippocampus of 
TauC3 mice. 
Immunohistochemical analysis of Tau in the brain of TauC3 mice. The 
cortex and hippocampus of 1.3 month-old WT and TauC3 mice were 
immunostained with HT7 and TauC3 antibodies. Scale bars, black: 400 μm, 














Figure 1-4. Rapid memory impairment in TauC3 mice.  
(A - C) Memory deficits in TauC3 mice. Wild-type (WT) and TauC3 mice 
were examined for their spatial memory with a Y-maze test (A), recognition 
memory with a novel object recognition test (B), and cognitive learning 














Figure 1-5. TauC3 mice does not show severe behavior abnormality. 
(A) TauC3 mice show similar motor function as wild-type mice do. Wild-
type (WT) and TauC3 mice were analyzed with a wire-hang test for their grip 
strength and cooperative motor function. Each group of mice was tested at 2, 
3, 6, 9, and 12 months of age. Data are means ± SEM (n = 19). (B) TauC3 
expression does not affect the hyperactivity or normal locomotor function in 
the mice. Total arm entries of wild-type (WT) and TauC3 mice in Y-maze test 













Figure 1-6. Reduced synaptic proteins in the hippocampus CA3 region of 
TauC3 mice at young age.  
(A-B) Hippocampal tissues were immunostained using synaptophysin 
antibody (mf) and Hoechst 33342 (py). mf; mossy fiber region, py, pyramidal 
region. Scale bars, 50 m. (A) Densitometric analysis of synaptophysin (Syn) 
on the fluorescence in A (B). (C-D) The hippocampal tissue lysates of wild-
type (WT) and TauC3 mice were examined with Western blot analysis (C) 
and the signals on the blot in C were quantified by densitometric analysis (D). 













Figure 1-7. Occurrence of TUNEL-positive cell death in aged TauC3 
mice. 
(A) The hippocampal CA3 and cortex regions of 12 month-old wild-type 
(WT) and 1.3, 6, and 12 month-old TauC3 mice were examined with 
TUNEL assay for dead cells and Hoechst dye staining (DAPI) for nuclei and 
then observed under fluorescence microscope. Scale bars, 50 μm. (B) The 
TUNEL-positive signals of the tissue slice were counted. Data are means ± 












Figure 1-8. Hematoxylin staining showing cell numbers in the 
hippocampus and cortex.  
(A) The hippocampal CA1 and CA3 and cortex regions of 12 month-old 
wild-type (WT) and 1.3, 3, 6, and 12 month-old TauC3 mice were stained 
with hematoxylin. (B) The numbers of hematoxylin-positive cells in (A) 
were counted. Data are means ± SEM (n = 3) (right). Scale bars, 100 μm, 














Figure 1-9. Lifespan analysis of TauC3 mice.  
Kaplan–Meier survival curve for TauC3 mice and wild-type (WT) 














Figure 1-10. Appearance of Tau hyperphosphorylation in TauC3 mice. 
(A) Hyperphosphorylation and conformational change of Tau in the 
hippocampus of TauC3 mice. The hippocampal tissue lysates prepared from 
wild-type (WT) and TauC3 mice were examined with Western blotting. (B) 
The signals on the blot in (A) were quantified by densitometric analysis. 














Figure 1-11. Detection of high molecular weight of Tau oligomers in 
TauC3 mice.  
(A) Effects of reducing agents on the formation of 170 kDa Tau oligomers. 
TauC3 brain extracts were incubated with or without beta-mercaptoethanol 
and/or DTT as indicated and then analyzed with Western blot analysis. (B) 
Hippocampal tissue lysates dissolved in non-reducing sample buffer were 
analyzed with Western blotting using the indicated antibodies. Arrows, Tau 
oligomers; arrowhead, monomeric Tau; n.s., nonspecific signal. (C) The 
signals on the blot B were quantified by densitometric analysis. Bars 
represent means ± SEM (n = 3). (D) The hippocampal tissue lysates 
prepared from 2 and 9 month-old wild type (WT), TauC3, and 3X TG mice 















Figure 1-12. Immunohistochemical analysis showing Tau oligomers in 
the hippocampal tissue of TauC3 mice.  
The CA3 region of the hippocampus of 6 month-old wild-type (WT) and 3 
and 6 month-old TauC3 mice were analyzed with immunohistochemistry 















Figure 1-13. The treatment with Aβ oligomers induces the formation of 
T22-positive tau oligomers in a caspase-dependent manner in cultured 
neurons.  
(A, B) Primary cortical neurons at DIV 14 were transfected with pEGFP, 
pEGFP-Tau, or pEGFP-TauC3 for 24 hr and then left untreated or treated 
with 5 M Aβ in the presence or absence of 20 μM caspase-3 inhibitor (z-
DEVD-fmk) for another 12 hr. The neurons were observed under 
fluorescence microscope. Scale bars, 10 μm (A, upper). The spine density of 
the neurons was examined by densitometric analysis. Bars represent means 
± SEM (***p < 0.001, *p < 0.05) (A, lower). In addition, the treated 
neurons were immunostained with T22 antibody (red) and observed under 












Figure 1-14. Caspase inhibitor blocks Tau cleavage and oligomer 
formation, and attenuates memory deficit in the Aβ oligomers-injected 
mice.  
(A) Experimental scheme of Aβ oligomer injection and memory test. Wild-
type (WT) at 6 months were i.c.v.-injected with PBS, caspase inhibitor IDN-
6556 (1 mM), or Aβ oligomers (15 μg) alone or together with caspase 
inhibitor IDN6556, as indicated. (B) Aβ oligomer injection induces memory 
impairment in a caspase-dependent manner. Spatial memory of each group 
(n = 7 - 8) of the mice was measured at 2 days after the injection. Bars 
represent means ± SEM (*p < 0.05). (C) Immunohistochemical analysis 
showing TauC3 and Tau oligomers in the hippocampus and cortex of the Aβ 
oligomer-injected mice. The hippocampus (CA1 region) and the cortex were 
prepared at 7 days after the injection and analyzed with 
immunohistochemistry using TauC3, T22, and AT8 antibodies. The same 
brain regions of 9-month old 3X-TG mice were used as controls. Scale bars, 












Figure 1-15. Detection of detergent (NP-40)-insoluble Tau aggregates 
in TauC3 mouse brain. (A)Wild-type (WT) and TauC3 hippocampal tissue 
lysates insoluble in RIPA buffer containing 0.5 % NP-40 were analyzed with 
Western blotting. (B) The signals on the blot (A) were quantified by 
densitometric analysis. Bars represent the relative ratio of NP-40-insoluble 
Tau (n = 3). (C) Tissue extracts of the hippocampus were analyzed with 
filter trap assay. (D) The signals on the blots of filter trap assay in (A) were 















Figure 1-16. Detection of silverstainig positive Tau aggregates with 
filamentous structure in TauC3 mice.  
(A) Silver staining-positive tangle formation in the Layer I and II of the 
cortex and the CA3 region of the hippocampal tissue of TauC3 mice. Scale 
bars, 50 m. (B) The 0.5% NP-40-insoluble hippocampal lysates were 
subjected to immunoprecipitation assay with Tau3 antibody cross-linked to 
protein A-beads. The immunoprecipitates and Tau aggregates which were 
prepared from purified Tau protein in the presence of heparin were observed 














Figure 1-17. Effects of methylene blue and Congo red on the filament 
formation of Tau protein in vitro and in cell model.  
(A) Purified Tau protein (10 M) was incubated with heparin (20 M) in the 
absence or presence of methylene blue (10 M) or Congo red (10 M). After 
being added with thioflavin T (25 M), the reaction mixtures were measured 
for the absorbance with spectrofluorometer. (B) SH-SY5Y cells were 
transfected with GFP-Tau alone or together with GSK3 for 16 h, after which 
cells were left untreated or treated with 20 mM LiCl, 3 μM (left panels) or 5 
μM, (right panels) doses of methylene blue (MB) and Congo red (CR) for 
additional 30 h. Cell lysates were analyzed with Western blotting (WB) and 















Figure 1-18. i.p. injection of Methylene blue or i.c.v. injection of Congo 
red retards the memory impairment in TauC3 mice.  
(A-C) Experimental scheme of drug treatments and memory tests. Wild-type 
(WT) and TauC3 mice at one month of age were i.p.-injected with 
Methylene blue(10 mg/kg/day) for 30 days or biweekly i.c.v.-injected with 
Congo red (75 g). Spatial memory of TauC3 mice was measured twice at 
1.3 months (10 days after injection) and 2 months (30 days after injection) 
of age and recognition memory was at 2 months of age (A). The mice were 
then examined for spatial memory with a Y-maze test (B) and recognition 
memory with a novel recognition test (C). Values are means ± SEM. (*p = 













Figure 1-19. Memory impairment of TauC3 mice is not attenuated by 
i.p.-injection of Congo red.  
Wild-type (WT) and TauC3 mice were examined for spatial memory with a 
Y-maze test at 2 months of age. Bars and values represent means ± SEM 














Figure 1-20. Methylene blue decreases the amounts of 170kDa Tau 
oligomers.  
The hippocampal tissue lysates dissolved in non-reducing sample buffer 
were analyzed with Western blotting under non-reducing condition. Arrows, 












Figure 1-21. Methylene blue preferentially decreases the amounts of 
TauC3 and PHF-1-positive tau.  
The hippocampal tissues were analyzed with Western blotting under 
reducing condition. The amount of total Tau (TG5) was a little changed by 













Figure 1-22. Immunohistochemical analysis showing the decrease of 
human TauC3 and tau oligomers by methylene blue in TauC3 mice.  
The CA3 regions of wild-type (WT) and TauC3 mice used in Fig. 6 were 
examined with immunohistochemical analysis using HT7 and T22 














Figure 1-23. Methylene blue rescues the loss of spine density and synaptic 
proteins in TauC3 overexpressed primary neuron and TauC3 mice.  
(A) Cultured hippocampal neurons (DIV 13) were transfected with GFP, 
GFP-tau, GFP-TauC3, or both GFP-tau and GFP-TauC3, after which cells 
were left untreated or treated with 50 nM methylene blue (MB) for 24 h. 
Scale bars, 10 μm. (B) The signals on the blots of filter trap assay in (A) 
were quantified by densitometric analysis. Data are means ± SEM (n = 3). 
(C) Wild-type (WT) and TauC3 mice (1 month of age) were daily i.p.-
injected with PBS or methylene blue (MB, 10 mg/kg/day) for 30 days. The 
hippocampal tissue lysates were prepared and examined with Western blot 















Figure 1-24. Rapamycin rescues the spatial and recognition memory 
impairment in TauC3 mice.  
(A) Wild-type (WT) and TauC3 mice were daily i.p.-injected from one 
month of age for 30 days with rapamycin (10 mg/kg). Spatial memory was 
measured twice at 1.3 months (10 days after injection) and 2 months (30 
days after injection) of age. (B) recognition memory was measured at 2 















Figure 1-25. Reduction of the phosphorylated tau and detergent-
insoluble tau aggregates by rapamycin in TauC3 mice. Hippocampal 
tissues examined in (1-35) were analyzed with Western blotting fractionated 
into RAB-soluble, RIPA-soluble and -insoluble (70% FA-soluble) fractions 














Figure 1-26. Enhanced autophagy markers in the rapamycin-treated 
hippocampal tissues of TauC3 mice. 
 Western blot is analyzed with LC3, p62and p-S6 antibodies for rapamycin 













Figure 1-27. Effect of rapamycin on the level of tau oligomers in TauC3 
mice.  
The hippocampal tissues examined in Figure 1-36 were analyzed with 
Western blotting under non-reducing condition. Arrows, tau oligomers; 

















Because of their association with toxicity, the roles of soluble oligomers and 
insoluble aggregates of disease-associated proteins have received 
considerable attention in many neurodegenerative diseases, such as Aβ and 
Tau oligomers in AD, Huntingtin oligomers in Huntington’s disease, and α-
synuclein oligomers in Parkinson’s disease (Haass and Selkoe, 2007). 
However, the presence and role of Tau oligomers and aggregates in animal 
models and AD pathogenesis are still poorly understood. TauC3 mice 
containing an oligomeric form of Tau show a strong association with memory 
deficits. In this mouse, detergent (0.5% NP-40)-soluble high molecular 
weight (around 170 kDa) of Tau was observed under a non-reducing condition. 
Similar sizes of Tau oligomers with approximately 130–200 kDa (Flach et al., 
2012), 140–170 kDa (Berger et al., 2007), 150 kDa (Sahara et al., 2007), and 
180 kDa (Patterson et al., 2011) were also previously detected with in vitro 
assays and in the brain of AD patients. Especially, compared to existing Tau 
mouse models, TauC3 in TauC3 mice was detected mainly in its oligomeric 
form, detected by Tau oligomer-specific antibody, T22. Because TauC3 was 






et al., 2003), TauC3 may form a self-oligomer or act as a seed to increase 
oligomers with endogenous mouse Tau (Rissman et al., 2004). While whether 
170 kDa Tau was a dimer or trimer was not clear, Tau low-n oligomers and 
aggregates appeared in TauC3 mice at an early age (1.3 months), which 
coincides with the onset of memory impairment in TauC3 mice.  
While TauC3 increases Tau phosphorylation and facilitates oligomer 
formation in the transgenic mice, the mechanism by which TauC3 affects 
memory impairment is currently unclear. The most prominent factor for the 
memory deficits observed in TauC3 mice may be TauC3 itself. According to 
our results, TauC3 evokes neurite regression and reduces synaptic density in 
cultured neurons and TauC3 mice. Consistently, methylene blue or rapamycin 
enhances memory function in TauC3 mice and increases synaptic density in 
primary neurons expressing Tau and TauC3. It appears that TauC3 exerts 
detrimental effects on synaptic density for memory loss. In addition, other 
groups have reported that TauC3 decreases mitochondria membrane potential 
and inhibits axonal transport, which leads to reduced synaptic button 
formation in cultured neurons (Quintanilla et al., 2009). Additionally, 
injection of a 120–170 kDa synthetic Tau oligomers or an AD brain-derived 
110–160 kDa Tau oligomers into mice has been shown to decrease 






long-term potentiation for memory impairment (Lasagna-Reeves et al., 2012). 
Thus, the synaptic dysfunction observed in TauC3 mice is attributed to TauC3 
oligomerization. 
While electronmicroscope-detectable Tau filaments are found from 1.3 
month of age, increasing up to 6 months, and silver staining-positive Tau 
aggregates were first found at 3 months in TauC3 mice, TUNEL-positive cell 
death was not observed until 6 month of age. TUNEL-positive cell death was 
barely detected at late stage in older TauC3 mice showing severe memory 
impairment. Thus, compared to wild-type mice, there was no visible 
reduction in total cell numbers in the affected tissues of TauC3 mice. Like 
TauC3, many AD model mice, including TG2576 mice and Tau P301L mice, 
do not always show visible neuronal loss in the cortex and hippocampus 
despite apparent memory loss (Chapman et al., 1999; Lewis et al., 2000). 
Similarly, in 24 month-old TauΔK280 TG mice, silver staining-positive Tau 
aggregates have been observed without significant neuronal loss (Terwel et 
al., 2005). Calignon et al. also observed caspase activation in the brains of 
rTG4510 mice and concomitant fast tangle formation without cell death in 
neurons within tangles (de Calignon et al., 2010). While detergent-insoluble 
Tau increases in TUNEL-positive cells in TauC3 model of D. melanogaster 






limited in TauC3 mice. 
Most striking finding in this study is that TauC3 mice exhibit memory 
deficits as early as at 2 months of age. This is compared to a non-mutated 
form of Tau, which usually leads to memory deficits in aged mice (> 9–18 
month) (Duff et al., 2000; Gotz et al., 1995) and to Tau P301L, a FTDP-17 
familiar Tau mutant that leads to memory deficits at 6 months (Terwel et al., 
2005). Though rTG4510 mice expressing Tau P301L show early memory 
deficits as in TauC3 mice, the expression level of Tau P301L is very high (> 
13-fold of endogenous mouse Tau). In this model, 9-fold overexpression of 
Tau P301L does not affect memory function (Santacruz et al., 2005). On the 
contrary, early memory deficits in TauC3 mice are not due to TauC3 
overexpression, since the expression of TauC3 is less than endogenous mouse 
Tau. It is also unlikely that the regional expression pattern of TauC3 driven 
by the promoter BAI1-AP4 plays an unexpected role, as TauC3 mice did not 
show other functional deficits, involving motor coordination that is typically 
linked to the striatum or cerebellum. The main factor responsible for the rapid 
memory deficit in TauC3 mice might be Tau oligomers which appear at young 
age. 
In the same context, methylene blue potently inhibited the formation 






TauC3 mice, though the data regarding the role of methylene blue is 
somewhat controversial (Hosokawa et al., 2012; O'Leary et al., 2010). In cell 
culture and TauC3 mice, it appears that methylene blue functions to decrease 
the amount of TauC3 oligomers and aggregates at low and non-toxic dose. On 
the other hand, it can also affect the amount of total Tau as well as Tau 
oligomers. Additionally, TauC3 mice were suitable to test the inhibitory effect 
of rapamycin on the memory impairment, as similarly tested in other Tau mice 
(Caccamo et al., 2010). Bearing in mind that the onset and duration of 
memory decline in other Tau mouse models occurs usually much later and 
take longer time, rapid loss of memory in TauC3 mice will help analyzing the 
effects of drug candidates on AD pathogenesis early on, as seen in our assays 
in which twice i.c.v. injection or short period of i.p. injection was enough for 
the assay.  
Taken together, TauC3 mice showed drastic memory impairment at 
an early age, associated with the appearance of Tau oligomers and aggregates. 
The memory impairment was remarkably rescued by drug candidate, which 
interfered with the formation of Tau oligomers and Tau aggregates and Tau 
level in the mice. I propose that TauC3 mice would be useful for analyzing 
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Essential role of POLDIP2  














In Alzheimer’s disease and other tauopathy, abnormal Tau proteins form 
intracellular aggregates and Tau filaments. However, the mechanisms that 
regulate Tau aggregation are not fully understood. In this paper, I show that 
POLDIP2 is a novel regulator of Tau aggregation. From a cell-based 
screening using cDNA expression library, I isolated POLDIP2 which 
increased Tau aggregation. Expression of POLDIP2 was increased in 
neuronal cells by the multiple stresses, including A, TNF- and H2O2. 
Accordingly, ectopic expression of POLDIP2 enhanced the formation of Tau 
aggregates without affecting Tau phosphorylation, while down-regulation of 
POLDIP2 alleviated ROS-induced Tau aggregation. Interestingly, I found that 
POLDIP2 overexpression induced impairments of autophagy activity and 
partially proteasome activity and this activities were retained in DUF525 
domain of POLDIP2. In a drosophila model of human tauopathy, knockdown 
of the drosophila POLDIP2 homolog, CG12162, attenuated rough eye 
phenotype induced by Tau overexpression. Further, the lifespan of neural-
TauR406W transgenic files were recovered by CG12162 knockdown. Together, 






aggregation via the impairment of autophagy activity, providing insight into 










Tau is a microtubule-associated protein that localizes mainly in the 
axon of neurons. Tau protein binds to and stabilizes microtubules and is 
highly soluble in normal condition (Schweers et al., 1994). On the contrary, 
Tau is hyperphosphorylated in AD and other tauopathies, during aging and 
under stress condition, leading to the formation of insoluble aggregates, 
known as neurofibrillary tangles (NFTs) in the affected neurons (Gotz et al., 
1995). In familiar type AD, several genes that are involved in generating Aβ 
(APP, PSEN1 and PSEN2) (Scheuner et al., 1996) or in frontotemporal 
dementia with parkinsonism 17, Tau itself (TAU P301L, R406W, V337M etc.) 
are closely related to onset of the disease (Hong et al., 1998). In most case (> 
95%) of chronic AD and tauopathy, however, no single gene induces these 
diseases, and both age-related memory loss and increases rate of disease 
occurs with aging. 
In general, the accumulation of Tau aggregates is critical for the 
pathogenesis in tauopathy. There seems to be a linkage between Tau 
aggregation and protein degradation machineries, the ubiquitin-proteasome 






mechanism for protein quality control through selective degradation of 
damaged/unfolded proteins (Ciechanover, 2005). Autophagy also degrades 
cytosolic materials from proteins to organelles, especially insoluble protein 
aggregates (Cuervo, 2008). Accordingly, altered UPS function and autophagy 
degradation are frequently found in chronic neurodegenerative diseases, such 
as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease 
(HD) and amyotrophic lateral sclerosis (ALS) (Baehrecke, 2005; 
Ciechanover and Brundin, 2003). In these diseases, reduced activity of the 
degradation systems is accompanied by accumulation of the aggregation-
prone proteins, such as Tau in tauopathy, including AD. However, cellular 
signal(s) and molecular determinant(s) responsible for the regulation of the 
degradation system and neuronal degeneration remain unknown. 
Reactive oxygen species (ROS) often contributes to the development 
of neurodegenerative diseases (Barnham et al., 2004). Levels of ROSs are 
elevated during aging and increased in Alzheimer’s disease (Christen, 2000). 
Mutant superoxide dismutase 1 (mSOD1) hetero knockout mice crossed with 
AD model mice show increased ROS and early impairment of 
learning/memory deficit (Bodendorf et al., 2002). Scavenging ROS 
suppresses neurotoxicity and reduces Tau aggregation, showing positive 






proposed contribution of ROS to neurodegeneration in vitro and in vivo, little 
is known about the molecular mechanism that ROS regulates the 
accumulation of aggregation-prone proteins underlying the neuropathology. 
POLDIP2 (also known as PDIP2, PDIP38) was first recognized as a protein 
that binds to DNA polymerase delta (Liu et al., 2003). POLDIP2 is predicted 
to interact with PCNA (Xie et al., 2005) and regulates NOX4 function in 
muscle cells (Lyle et al., 2009). However, the role of POLDIP2 in 
neurodegenerative disease is not understood. 
In this paper, I identified POLDIP2 as an important modulator of Tau 
aggregation. I showed that POLDIP2 regulated Tau aggregation via the 








Materials and methods 
 
 
Cell culture and DNA transfection 
Cell culture was previously described (Park et al., 2012). HEK293T, HeLa 
and SH-SY5Y cells were cultured in DMEM (Hyclone) supplemented with 
10% (v/v) fetal bovine serum (Hyclone). Primary cortical neurons were 
prepared from mouse brains at embryonic day 16. The neurons were seeded 
on poly-L-lysine (0.01% in 100 mM borate buffer, pH 8.5)-coated plates and 
maintained in neurobasal medium containing 2% B-27 supplement 
(Invitrogen) and 0.5 mM L-glutamine. Half of the medium was exchanged 
every 3 days. HEK293T and SH-SY5Y cells were transfected using the 
Polyfect reagent (Qiagen). 
 
Western blotting and antibodies 
The lysates were prepared as described previously (Kam et al., 2013). The 
blots were blocked for 1 h and incubated with following antibodies: PHF-1, 
TG5 (a generous gift from Dr. P. Davies, Albert Einstein College of Medicine, 
USA), P3R and P8R (a gift from Dr. E. Klaile, Karolinska Institute, Sweden), 






ULK1, and p-ULK1 (Cell signaling) antibodies. Membranes were rinsed and 
incubated for 1 h with peroxidase-conjugated anti-mouse or rabbit antibody 
and visualized using the ECL detection system. 
 
Filter trap assay for Tau aggregates 
SH-SY5Y cells transfected with pcDNA3-HA and pPOLDIP2-HA with GFP-
Tau cDNA and The lysates were prepared as described previously (Park et al., 
2012). After brief sonication, equal amounts of cell lysates were passed 
through a nitrocellulose filter (0.2 mm). The membrane was washed three 




To construct serial deletion mutants of human POLDIP2 (BC000655.2, 
polymerase delta-interacting protein 2 isoform 2), POLDIP2-WT (amino 
acids 1–368), POLDIP2-A (amino acids 201–368), POLDIP2-B (1–200), and 
POLDIP2-C (1–72) were amplified by PCR using gene-specific synthetic 
DNA oligonucleotides and subcloned into p3xFLAG-CMV-14. 
 






Method for the assay is previously described (Shim et al., 2012). After 
preparation of cell lysates in lysis buffer, proteasome activities were measured 
using the fluorogenic substrates Suc-LLVY-AMC, Bz-VGR-AMC and Ac-
GPLD-AMC (Biomol) and a fluorometer (FlexStation 3 Microplate Reader; 
Molecular Devices). The excitation and emission wavelengths were 380 and 
460 nm, respectively.  
 
Reverse transcription-PCR 
Drosophila whole body were lyzed and total RNA was purified using Trizol 
reagent (Invitrogen) according to the manufacturer’s protocol. PCR was 
performed using following synthetic oligonucleotides sets: CG12162 (5′- 
CCT CGA CCG CCT TTG AGA CGA ACG-3′, 5′- CGA GGT TCT CCA 
GTC GGA TGC AGT -3′), RP49 (5′- ATG ACC ATC CGC CCA GC-3′, 5′- 
CTC GTT CTC TTG AGA ACG-3′). 
 
Small interfering RNA (siRNA) transfection  
The siRNA oligonucleotides against POLDIP2 (#1, 1119184; #2, 1119188; 
#3, 1119189) and scrambled control were purchased (Bioneer) and RNA 








D. melanogaster was raised in the dark at 25°C. WT (w1118) and POLDIP2 
mutant (CG12162EY08866) strains used in this study were obtained from the 
Bloomington Drosophila Stock Center at Indiana University. The gl-tau2.1 line 
was kindly provided by Dr. D. Geschwind (University of California, USA) 
(Jackson et al., 2002). UAS-tauR406W fly line for the generation of elav-tau406W 




More than 200 files of each genotype were collected, divided into tubes of 10 
flies and incubated at 29°C on the standard food. The culture medium was 













Identification of POLDIP2 as an inducer of Tau aggregation 
To find out new regulator(s) of Tau protein aggregation, I screened 5,000 
cDNAs encoding protein kinases, membrane proteins and other proteins that 
are expressed in the brain and are associated with human diseases (Shim et 
al., 2012). With the cell-based assay using GFP-Tau, GFP allowed the 
detection and formation of Tau aggregates under a fluorescence microscope. 
During the screening, transfection efficiency was normalized by 
cotransfection with monomeric RFP. GFP-positive dots were counted as 
aggregates of the Tau. From screening using the expression library, I could 
isolate putative positive cDNA clones (Fig. 2-1A and B). Ectopic expression 
of the putative positive clones enhanced the aggregation of GFP-Tau in the 
transfected cells (Fig. 2-1B). In particular, POLDIP2 overexpression 
exhibited strong effects on the aggregation of GFP-Tau (Fig. 2-1C) and 
induced neuronal cell death (Fig. 2-1D) in a dose-dependent manner.  
 
The expression of POLDIP2 is increased by reactive oxygen stress for 






Then I investigated the signal that might regulate the expression of 
POLDIP2. Interestingly, I found that treatment with amyloid beta1-42 (Aβ), a 
pathogenic factor of AD (Kam et al., 2013), tumor necrosis factor alpha 
(TNF-) or H2O2 increased the expression of POLDIP2 in mouse primary 
hippocampal neurons, while other signals did not affect it (Fig. 2-2A). All 
these signals are believed to be crucial in many neurodegenerative disease 
(Schwab and McGeer, 2008). Among these signals, I focused on ROS because 
this signal is highly associated with sporadic type of neurodegenerative 
disease but its mechanism is not known yet (Glass et al., 2010). Treatment 
with H2O2 also increased POLDIP2 expression in SH-SY5Y human 
neuroblastoma cells (Fig. 2-2B). 
Next, I addressed whether ROS could affect Tau aggregation. The results 
from cell-based GFP-Tau dot formation assay showed that treatment with 
H2O2 increased the numbers of GFP-Tau aggregates in SH-SY5Y cells (Fig. 
2-3A). In addition, H2O2 increased the amounts of detergent-insoluble tau 
aggregates on filter-trap assay (Fig. 2-3B). With the notion that POLDIP2 
expression was induced by ROS, I examined whether POLDIP2 was involved 
with the aggregation of Tau. I found that POLDIP2 expression was 
significantly reduced by POLDIP2 siRNA#1 and 2, and marginally by 






expression by POLDIP2 siRNA#1 or 2, but not POLDIP2 siRNA#3, inhibited 
ROS-induced Tau aggregates (Fig. 2-3D). These results indicate that 
POLDIP2 is critical in Tau aggregation induced by ROS. 
 
Increased POLDIP2 impairs autophagy activity 
Many studies have shown that the aggregation of Tau protein is 
accompanied by Tau hyperphosphorylation, a typical pathophysiologic 
modification of Tau (Park et al., 2012). When I examined Tau 
phosphorylation with western blot analysis, however, ROS or overexpression 
of POLDIP2 did not much affect the phosphorylation status of Tau protein 
(Fig. 2-3B). These results led us to address a possibility that POLDIP2 might 
interfere the clearance of Tau protein by affecting autophagy and UPS. In 
addition, it was shown that multiple stresses, including ROS and Aβ, impair 
the activity of affect autophagy flux (Scherz-Shouval and Elazar, 2011) and 
proteasome complex (Aiken et al., 2011). Especially, aggregation-prone 
proteins, including Tau aggregates, are believed to be clarified by autophagy 
(Wang et al., 2009). 
Thus, I examined whether POLDIP2 affected autophagy activity using 
mCherry-GFP-LC3. In the mCherry-GFP-LC3 assay, inhibition of lysosomal 






localization of acid-labile GFP-LC3 in autolysosomes, while acid-sensitive 
GFP signals normally disappear in autolysosomes. Interestingly, I found that 
overexpression of POLDIP2 drastically increased the formation of 
colocalized mCherry-GFP dots and reduced the numbers of mCherry-only 
cells (Fig. 2-4A), indicating an inhibition in late autolysosome function 
(Pankiv et al., 2007). Accordingly, I found that overexpressed POLDIP2 
greatly increased the levels of LC3 II and p62 (Fig. 2-4B), an ubiquitin-
binding autophagy receptor (Lamark et al., 2009). Consistent to the recent 
report (Brown et al., 2014), knockdown of POLDIP2 expression enhanced 
autophagy activity (Fig. 2-4C). These results strongly suggest that increased 
POLDIP2 impairs autophagy. I further assessed proteasome activity and 
found that ROS inhibited enzymatic activity of proteasome in SH-SY5Y cells 
(Fig. 2-5A). Knockdown of POLDIP2 expression partially but not much 
rescued the impairment of proteasome activity by ROS (Fig. 2-5B). In 
addition, ectopic expression of POLDIP2 marginally increased the 
accumulation of unstable degron (Fig. 2-5C) and suppressed proteasome 
activity (Fig. 2-5D).   
 







The POLDIP2 has 2 distinct domains; Yccv-like domain and DUF525 
domain (Brown et al., 2014). To define the domain(s) responsible for Tau 
aggregation, several deletion mutants of POLDIP2 were generated (Fig. 2-
6A). From western blot analysis, I observed similar levels of expression 
among POLDIP2 full-length and two deletion mutants except POLDIP2-C 
mutant which was not expressed in the transfected cells (Fig. 2-6B). Like 
POLDIP2, POLDIP2-A mutant containing the DUF525 domain only 
effectively increased Tau aggregation, while POLDIP2-B mutant containing 
the Yccv-like domain and POLDIP2-C mutant lacking both Yccv-like 
domain and DUF525 domain did not stimulate Tau aggregation (Fig. 2-6C).  
Interestingly, I found that POLDIP2-A containing the DUF525 domain 
only, but not POLDIP2-B mutant, increased colocalization of mCherry and 
GFP dots and reduced the numbers of mCherry-only cells as much as 
POLDIP2 did (Fig. 2-6D). These results indicate that the DUF525 domain is 
crucial for autophagy inhibitory function of POLDIP2 and suggest a strong 
correlation between Tau aggregation and autophagy inhibition exhibited by 
POLDIP2. Unlike their effects on autophagy inhibition, I could not find any 
clear correlation between Tau aggregation by the POLDIP2 mutants and their 







POLDIP2 knockout rescues human Tau-mediated neural degeneration 
in drosophila 
To assess an in vivo role of POLDIP2 in Tau pathology, I used a drosophila 
model expressing Tau in the eye (Jackson et al., 2002) and whole-neurons 
(Wittmann et al., 2001). The flies with the retinal overexpression of human 
Tau (gl-tau2.1) showed moderate toxicity, characterized by the loss of 
photoreceptor neurons, leading to observation in drosophila eye as a rough 
surface (Fig. 2-8A). The CG12162 gene has been identified as a fly homolog 
of the POLDIP2 and 1 p-element insertion mutant line (Bloomington stock 
No.17500, CG12162EY08866) showed reduced level of CG12162 mRNA (Fig. 
2-9A). Then I reconstituted the knockout flies (CG12162ΔEY08866) by ejecting 
p-element from CG12162EY08866 flies. Compared with that in control flies 
(w1118), there was no detectible difference in the eye morphology of CG12162 
knockout flies or CG12162ΔEY08866 reconstituted flies (Fig. 2-8A, left 3 
panels).  
Then I crossed CG12162EY08866 mutant or CG12162ΔEY08866 reconstitution 
flies with gl-tau2.1 Tau flies. Interestingly, knockdown of fly POLDIP2 
homologue in the retina of Tau transgenic flies (gl-tau2.1/CG12162EY08866) 
markedly rescued Tau-induced retinal degeneration. On the contrary, 






again caused rough eye phenotype (Fig. 2-8A, right 3 panels). These 
observations indicate that POLDIP2 level is critical in Tau-induced 
neurotoxicity in the flies. Compared with Tau transgenic flies, the results from 
western blot analysis revealed that Tau phosphorylation at PHF-1 epitope (Ser 
396/404) was not affected by knockdown of fly POLDIP2 homologue in the 
fly eye expressing Tau (gl-tau2.1/CG12162EY08866) (Fig. 2-9B), consistent to 
those of our cell models. Similarly, other Drosophila tau model also showed 
that ROS exacerbates tau toxicity without altering tau phosphorylation (Dias-
Santagata et al., 2007). 
Further, I crossed wild-type, CG12162 mutant or CG12162 reconstitution 
flies with TauR406W flies which express TauR406W in whole neurons (Wittmann 
et al., 2001), and compared their lifespan. Tau flies (elav-gal4;UAS-TauR406W) 
exhibited shorter lifespan (average 35 days) than control flies (elav-gal4/+, 
average 45 days). When Tau flies were crossed with POLDIP2 mutant flies 
(CG12162EY08866) or reconstituted flies (CG12162ΔEY08866), the lifespan was 
significantly extended by POLDIP2 deficiency (average 42 days in elav-gal4; 
UAS-TauR406W/CG12162EY08866) but not in the reconstituted line (average 35 
days in elav-gal4; UAS-TauR406W/CG12162ΔEY08866) (Fig. 2-8B). Thus, these 
observations further support that POLDIP2 plays an important role in Tau-






Figure 2-1. Isolation of POLDIP2 as a regulator of Tau aggregation. (A) 
The 5,000 cDNAs in mammalian expression vector were screened by a cell-
based assay using GFP-Tau, as shown in scheme. (B) SH-SY5Y cells were 
transfected with GFP-Tau alone or together with GSK3 or putative positive 
clones for 24 h. Cells showing Tau aggregates were counted under 
fluorescence microscope. (C) SH-SY5Ycells were transfected with GFP-Tau 
and the increasing amounts of POLDIP2 for 24 h and GFP-Tau aggregation 
was then analyzed under microscope. (D) SH-SY5Ycells were transfected 
with POLDIP2 for 24 h and cell death was analyzed. Data are means ± S.D. 















Figure 2-2. POLDIP2 expression is increased by oxidative stress in SH-
SY5Y cells and cultured primary neurons.  
 (A) Primary cortical neurons were treated with 50 ng/ml TNF-, 200 M 
H2O2 or 5 M A and then analyzed by western blotting. (B) SH-SY5Y 
cells were incubated with the increasing doses of H2O2 for 24 h and analyzed 













Figure 2-3. Knockdown of POLDIP2 expression inhibits oxidative stress-
induced Tau aggregation. 
(A) SH-SY5Y cells were transfected with GFP-Tau and then incubated with 
200 M H2O2 for 24 h. Tau aggregates were then observed under fluorescence 
microscope. (B) Samples from (A) were analyzed by filter-trap assay and 
Western blot. (C) SH-SY5Y cells were transfected with POLDIP siRNA (#1, 
2, and 3). After 48 h, cells were analyzed for POLDIP2 knockdown by 
western blotting. (D) SH-SY5Y cells were cotransfected with POLDIP siRNA 
and GFP-Tau. After 48 h, Tau aggregation were analyzed under fluorescence 












Figure 2-4. POLDIP2 expression impairs autophagy flux.  
(A) HeLa cells were cotransfected with POLDIP2 and GFP-mCherry-LC3 
for 24 h. Numbers of RFP only-positive or GFP/RFP-colocalized cells were 
counted and represented as bar graph. (B) SH-SY5Ycells were transfected 
with POLDIP2 and cell lysates were analyzed with western blotting. (C) SH-
SY5Y cells were cotransfected with GFP-LC3 and POLDIP2 siRNA (#1, 2, 
and 3) and GFP-LC3 dot formation was counted under fluorescence 













Figure 2-5. Increased POLDIP2 impairs proteasome activity.  
SH-SY5Y cells were incubated with 200μM H2O2 for 24 h and 
chymotrypsin-like proteasome activity was measured using Suc-LLVY-AMC 
(A). SH-SY5Y cells were transfected with POLDIP2 siRNA (#1, 2 or 3). 
After 48 h, cells were treated with 200μM H2O2 for additional 24 h and 
analyzed for proteasome activity (B). SH-SY5Y cells were cotransfected 
POLDIP2 with green fluorescent protein tagged with CL1 (GFPu) for 36 h 
and then analyzed by western blotting (left) and the signals on the blot were 
quantified by densitometric analysis (right) (C). SH-SY5Y cells were 
transfected with POLDIP2 (400 and 800 ng/ml) for 24 h and chymotrypsin-
like activity was then measured using Suc-LLVY-AMC (D). Data are means 














Figure 2-6. POLDIP2 regulates Tau aggregation and autophagy flux 
through its DUF525 domain.  
(A) Schematic diagram of POLDIP2 domains and its deletion mutants. 
Numbers indicate amino-acid residues of human POLDIP2. (B) Western blot 
analysis showing expression of the transfected POLDIP2 wild-type (WT) and 
3 deletion mutants in HEK293T cells. (C-D) SH-SY5Y cells were 
cotransfected with POLDIP2 deletion mutants and GFP-Tau (C) or GFP-
mCherry-LC3 (D). After 24 h, Tau aggregation (C) and LC3 puncta formation 
(D) were examined under microscope. The effects of POLDIP2 mutants on 
Tau aggregation and autophagy activity are summarized in (A). Data are 












Figure 2-7. POLDIP2 does not affect proteasome activity. 
(A) SH-SY5Y cells were transfected with POLDIP2 deletion mutants. After 
24 h, proteasome activity were measured using GFPU accumulation. (B) Cell 
lysates from (A) were analyzed for proteasome activity using the fluorogenic 













Figure 2-8. Knockdown of POLDIP2 expression rescues Tau toxicity in a 
Drosophila model.  
(A) WT (w1118) and POLDIP2 knockdown mutant (CG12162EY08866), and 
POLDIP2-reconstituted (CG12162ΔEY08866) flies were crossed with flies 
showing tau rough eye (gl-tau2.1), generating double transgenic fly lines (gl-
tau2.1/CG12162EY08866 and gl-tau2.1/CG12162ΔEY08866). Eye morphology of 
each line was examined. (B) Flies expressing TauR406W in whole body neurons 
(elav-gal4; UAS-TauR406W) were crossed with POLDIP2 knockdown mutant 
flies, generating double transgenic flies (elav-gal4; UAS-
TauR406W/CG12162EY08866) and with POLDIP2-reconstituted flies, generating 
double transgenic flies (elav-gal4; UAS-TauR406W/CG12162ΔEY08866). Flies 
were collected at 1 day after eclosion and lifespan was measured at 29°C (n 














Figure 2-9. Deficiency of Drosophila POLDIP2 homologue in flies does 
not alter Tau phosphorylation.  
(A) Total RNA was purified from wild-type (w1118) and POLDIP2 
knockdown mutant (CG12162EY08866) and analyzed with RT-PCR. (B) WT 
(w1118) and POLDIP2 mutant (CG12162EY08866), and POLDIP2-reconstituted 
(CG12162ΔEY08866) flies were crossed with the flies showing tau rough eye 

















Despite the discrepancy between Tau protein aggregation and 
neurodegeneration, NFTs are considered as a major pathogenic factor in 
tauopathy. Intracellular accumulation of Tau and neurofibrillary degeneration 
are hallmark of tauopathies, including AD. In this study employing genome-
wide screening and subsequent characterization, I found that POLDIP2 is an 
important player in Tau aggregation and Tau-associated neuropathology. 
Unlike other pathogenic mediators, such as GSK3 and Cdk5 (Yamaguchi et 
al., 1996), in Tau aggregation, POLDIP2 does not alter Tau phosphorylation 
but regulates Tau degradation/clearance system. Especially, it is interesting to 
note that the POLDIP2 regulates autophagy flux through DUF525 domain 
which consists of two subdomains, ApaG and F-box c-terminal like 
subdomain and is predicted to be involved in protein-protein interactions 
(Winston et al., 1999). 
 Though POLDIP2 was reported as a polymerase delta interaction 
protein (Liu et al., 2003), it seems to be a multifunctional protein. POLDIP2 
is also known as a regulator of NOX4; in smooth muscle cells, POLDIP2 






(Rho kinase) increases Tau-mediated neurodegeneration and RhoA and Rock 
inhibition by Rock inhibitor reduces Tau protein level (Hamano et al., 2012). 
Also, RhoA and Rock inhibition stimulates protein degradation system (Bauer 
et al., 2009). Thus, POLDIP2 might form a positive feedback loop under ROS 
stimulation and inhibits protein degradation pathways. Although the previous 
studies showed that autophagy is upregulated in POLDIP2 knockout mouse 
embryo fibroblasts (Brown et al., 2014), the mechanism by which POLDIP2 
regulates autophagy remains to be addressed.  
Autophagy and proteasome activities are declined during aging, while 
ROS are increased. Thus, dysregulation of these factors affects longevity and 
accelerates aging (Min et al., 2008; Rubinsztein et al., 2011). In addition to 
its effect on aging, global autophagy impairment also causes the aggregation 
of misfolded proteins, which is associated with perturbation of cellular 
functions and various human disorders. Moreover, ROS is an important 
pathophysiological feature of many neurodegenerative diseases and 
exacerbates the progression of neurodegenerative diseases (Nixon, 2013). 
Consistently, neurodegenerative model mice with SOD mutation show 
neurodegeneration with multiple protein aggregation (Bodendorf et al., 2002). 
Most studies, however, have focused on the degradation systems of the 






Shouval and Elazar, 2007). On the other hand, our study illustrates an 
important mediator, POLDIP2, of ROS to impair autophagy pathway. Thus, 
enhancement of autophagy activity by the inhibition of POLDIP2 may 
provide an insight into manipulation of Tau-associated neuronal degeneration, 
as evidenced by the Tau fly model with POLDIP2 deficiency.  
In conclusion, I propose that POLDIP2 plays an important role in a 
tauopathy model through the regulation of autophagy activity, linking the 
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알츠하이머 병(alzheimer’s disease)과 다른 tau에 의한 퇴행성 
뇌질환에서 tau 단백질은 세포내 응집현상(aggregated) 과 filament를 
형성한다. 이러한 tau의 중합체(oligomer)들은 이러한 
퇴행성질환에서 신경독성을 일으키는 가장 큰 원인 중 하나로 
알려져 있다. 그러나 이러한 Tau단백질의 aggregation의 형성과 
조절에 관련된 기작이나 유전자에 대해서 아직 밝혀지지 않은 
부분이 많다. 이 논문에서는 tau 단백질 중합체를 빠르게 형성하는 
모델동물을 만들고 tau 단백질의 응집현상을 조절하는 유전자를 
찾아내어 관련기작의 이해를 더욱 증진시키고자 하였다.  
알츠하이머 환자의 뇌에서는 활성화된 caspase가 tau 단백질의 
421번째 aspartic acid를 절단하는 일이 발생하며, 이에 생성된 
절단된 형태의 tau 단백질(TauC3)은 in vitro 상태에서 빠르게 tau 
단백질 중합체를 이룬다는 사실을 잘 알려져 있었으나 in vivo 
상태에서 연구는 미진한 상태였다. 신경 특이적으로 TauC3 
단백질을 발현하는 쥐 모델을 만들어 분석한 결과 1.3개월부터 






증가와 함께 나타나는 것을 볼 수 있었다. 또한 복강주사(i.p.) 또는 
뇌강내 주사(i.c.v.)를 통한 메틸렌블루나 콩고레드와 같은 tau 중합 
억제제 투여나 rapamycin과 같은 자가포식작용(autophagy) 촉진제 
투여시 기억력의 향상이 tau 중합체 감소와 수반되어 나타나는 
것을 관찰 할 수 있었다. 이를 통해 tau 단백질 중합체의 형성이 
tau 관련 퇴행성 뇌질환과 비례적으로 나타나며 이 과정에서 
TauC3 형태의 tau 단백질이 중요한 역할을 함을 알 수 있다. 
또한 이 논문에서 우리는 tau 응집현상을 조절하는 새로운 
유전자로 POLDIP2를 동정했다. POLDIP2는 치매 환자의 뇌가 
노출된 유해한 환경을 대변하는 아밀로이드 베타(Aβ), TNF-α, 또는 
과산화수소 등에 의해 양이 증가하였다. 또한 POLDIP2를 과발현 
시킨 경우 tau의 인산화에는 크게 영향을 미치지 않으나 tau 
응집현상은 크게 증가시키며 POLDIP2 발현을 감소시킨 경우 
과산화수소 처리에 의한 POLDIP2 증가에 의해 나타나는 tau 
단백질 응집현상의 증가가 나타나지 않는 것을 발견했다. 이러한 
POLDIP2의 tau 단백질 응집현상 조절은 본 단백질의 DUF525 
영역에 기반한 자가포식작용 (autophagy)과 일부 유비퀴틴에 의한 






조절을 통해 이루어진다. POLDIP2의 초파리 유사유전자인 
CG12162의 돌연변이를 이용한 실험에서 Tau가 눈에서 과발현 된 
초파리 모델에서 CG12162의 발현을 감소시키면 초파리의 눈의 
망가짐이 완화되는 것을 확인하였고 TauR406W가 신경세포에서 
과발현 되어 수명을 단축하는 초파리 모델에서 CG12162의 발현 
감소가 수명을 증가시키는 것을 확인하였다. 이러한 관찰을 통해 
POLDIP2가 tau 단백질 응집을 자가포식작용을 통해 조절하는 
유전자로 동정하였으며, 이를 통해 tau 응집현상의 분자기작을 
이해에 기여를 한다 할 수 있겠다. 
